Endoscopic Delivery of Fecal Biotherapy in Inflammatory Bowel Disease

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

The intestinal microbiome plays an important role in the pathogenesis of inflammatory bowel disease (IBD). We are able to use the microbiome as a therapeutic target with use of fecal microbiota transplantation (FMT) for cure of recurrent Clostridium difficile infection. Given our ability to target the dysbiotic state with FMT, its use as therapy in IBD has tremendous potential. This overview discusses the practical considerations of FMT therapy with respect to our current understanding of safety and efficacy in IBD, screening for donors and recipients, specimen handling and storage, methods of delivery, and regulatory considerations.

Original languageEnglish (US)
Pages (from-to)707-717
Number of pages11
JournalGastrointestinal Endoscopy Clinics of North America
Volume26
Issue number4
DOIs
StatePublished - Oct 1 2016

Keywords

  • Dysbiosis
  • Fecal Microbial Transplant (FMT)
  • Inflammatory Bowel Disease (IBD)
  • Microbiome
  • Recurrent Clostridium Difficile Infection (RCDI)

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Endoscopic Delivery of Fecal Biotherapy in Inflammatory Bowel Disease'. Together they form a unique fingerprint.

Cite this